Click to view our accessibility statement Delivering on HopeTM
  • About Us
    • About Neurocrine
    • Leadership Team
      • Management Team
      • Board of Directors
    • Culture & Values
      • Patient Access & Pricing
      • Diversity & Equality
    • News & Events
    • Webcasts & Presentations
    • Contact Us
  • Patients & Families
    • Overview
    • Tardive Dyskinesia
    • Parkinson’s Disease
    • Congenital Adrenal Hyperplasia
    • Chorea in Huntington Disease
    • Epilepsy
    • Women’s Health
    • Psychiatric Disorders
  • Products
  • Pipeline
    • OVERVIEW
    • Congenital Adrenal Hyperplasia
      • Crinecerfont
        • Clinical Trials
    • Chorea in Huntington Disease
      • Valbenazine
        • Clinical Trials
    • Women’s Health
      • Polycystic Ovary Syndrome
    • Psychiatric Disorders
      • Schizophrenia
        • Luvadaxistat (NBI-1065844/TAK-831)
          • Clinical Trials
      • Treatment-Resistant Depression
        • NBI-1065845 (TAK-653)
      • Anhedonia
        • NBI-1065846 (TAK-041)
    • Epilepsy
      • NBI-827104
        • Clinical Trials
      • NBI-921352 (XEN901)
    • Additional Pipeline Programs
  • Careers
    • Overview
    • Culture and Values
    • Benefits
    • Recruitment Agencies
  • Investors
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Shareholder Contacts
    • Partners/Collaborators
    • Annual Meeting
    • Online Annual Reports
    • Ownership
    • Email Alerts
    • Corporate Governance
    • Corporate Sustainability
    • Webcasts & Presentations
  • Contact Us

Badge – thumbnail

Careers

  • Overview
  • Culture and Values
  • Benefits
  • Recruitment Agencies
  • ©2021 Neurocrine Biosciences, Inc.
  • All Rights Reserved.
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Accessibility
  • Sitemap

You are now leaving the Neurocrine website.

Neurocrine is not responsible for the content of linked third party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.

Leave Site

By continuing to use this site, you agree to our use of cookies
as described in our Cookie Policy.